Company / PP&E (Net)
Alaunos Therapeutics, Inc. PP&E (Net) History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$91.0K
FY2025
5-year range
$0 / $10.9M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) returned to growth in FY2025 after 3 years of decline, reaching $91,000.
Based on SEC 10-K filings.
$91,000 in FY2025 with a 5-year CAGR of -61.1%.
Improved from $2,000 to $91,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -77.9%
- 5-Year CAGR
- -61.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -61.1%, indicating a declining trend.
- Peak pp&e (net) was recorded in FY2021.
- Lowest pp&e (net) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $91.0K | - |
| FY2024 | $0 | -100.0% |
| FY2023 | $2.0K | -100.0% |
| FY2022 | $8.5M | -22.7% |
| FY2021 | $10.9M | +6.9% |
| FY2020 | $10.2M | +821.7% |
| FY2019 | $1.1M | +1.2% |
| FY2018 | $1.1M | +37.0% |
| FY2013 | $801.0K | -59.8% |
| FY2012 | $2.0M | +74.8% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026